Free shipping on all orders over $ 500

Demcizumab

Cat. No. M24588
Demcizumab Structure
Synonym:

OMP 21M18 Human Anti-TNFRSF10B Recombinant Antibody

Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models.

Chemical Information
CAS Number 1243262-17-0
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Jose Alejandro Perez-Fidalgo, et al. Ann Transl Med. NOTCH signalling in ovarian cancer angiogenesis

[2] Huizhong Xiong, et al. Theranostics. Spleen plays a major role in DLL4-driven acute T-cell lymphoblastic leukemia

[3] Robert L Coleman, et al. Gynecol Oncol. Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial

[4] Mark J McKeage, et al. Target Oncol. Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC

[5] David C Smith, et al. Clin Cancer Res. A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors

Related Notch Products
Jagged-1 (188-204)

Jagged-1 (188-204) is a fragment of the Jagged-1 (JAG-1) protein with Notch agonist activity.

DAPM

DAPM is a Notch pathway inhibitor with anticancer activity and antiproliferative effects.

Procyanidin B2 3,3'-di-O-gallate

Procyanidin B2, 3,3'-di-O-gallate is an active constituent. Procyanidin B2, 3,3'-di-O-gallate strongly suppresses the constitutive as well as Jagged1 (Notch1 ligand)-induced activated Notch1 pathway.

SAHM1 TFA 

SAHM1 TFA is a Notch pathway inhibitor. SAHM1 TFA stabilizes hydrocarbon-stapled alpha helical peptide. SAHM1 TFA targets the protein-protein interface and prevents Notch complex assembly.

JI051 

JI051 is a stabilizer for the Hes1-PHB2 interaction. JI051 interacts with a cancer-associated protein chaperone prohibitin 2 (PHB2), induces cell-cycle arrest by inhibiting the Notch downstream effector gene Hes1. Anti-cancer activity.

  Catalog
Abmole Inhibitor Catalog




Keywords: Demcizumab, OMP 21M18 Human Anti-TNFRSF10B Recombinant Antibody supplier, Notch, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.